KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Encompass Health (EHC) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Encompass Health (EHC) over the last 17 years, with Q3 2025 value amounting to $48.7 million.

  • Encompass Health's Cash & Equivalents fell 6705.01% to $48.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.7 million, marking a year-over-year decrease of 6705.01%. This contributed to the annual value of $85.4 million for FY2024, which is 2358.9% up from last year.
  • Per Encompass Health's latest filing, its Cash & Equivalents stood at $48.7 million for Q3 2025, which was down 6705.01% from $99.1 million recorded in Q2 2025.
  • In the past 5 years, Encompass Health's Cash & Equivalents registered a high of $223.9 million during Q1 2021, and its lowest value of $21.8 million during Q4 2022.
  • Moreover, its 5-year median value for Cash & Equivalents was $85.4 million (2024), whereas its average is $97.0 million.
  • Per our database at Business Quant, Encompass Health's Cash & Equivalents crashed by 8540.0% in 2021 and then surged by 21697.25% in 2023.
  • Encompass Health's Cash & Equivalents (Quarter) stood at $49.4 million in 2021, then plummeted by 55.87% to $21.8 million in 2022, then skyrocketed by 216.97% to $69.1 million in 2023, then grew by 23.59% to $85.4 million in 2024, then tumbled by 42.97% to $48.7 million in 2025.
  • Its Cash & Equivalents was $48.7 million in Q3 2025, compared to $99.1 million in Q2 2025 and $95.8 million in Q1 2025.